Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of “Moderate Buy” from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received an average rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $82.2857.

TARS has been the subject of a number of recent analyst reports. Barclays assumed coverage on Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 target price for the company. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen raised shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th.

Tarsus Pharmaceuticals Trading Up 1.6%

Shares of NASDAQ:TARS opened at $66.61 on Friday. The business’s 50 day simple moving average is $72.54 and its 200 day simple moving average is $67.82. Tarsus Pharmaceuticals has a 1 year low of $38.51 and a 1 year high of $85.25. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.29 and a quick ratio of 4.25. The company has a market capitalization of $2.83 billion, a P/E ratio of -32.98, a P/E/G ratio of 0.96 and a beta of 0.57.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the completion of the transaction, the chief executive officer owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dianne C. Whitfield sold 7,397 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the sale, the insider owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. This represents a 15.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 8.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Invesco Ltd. lifted its holdings in shares of Tarsus Pharmaceuticals by 8.0% in the fourth quarter. Invesco Ltd. now owns 1,012,357 shares of the company’s stock worth $82,892,000 after acquiring an additional 75,351 shares during the last quarter. Mackenzie Financial Corp acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth approximately $202,000. XTX Topco Ltd lifted its stake in Tarsus Pharmaceuticals by 270.3% in the 4th quarter. XTX Topco Ltd now owns 18,410 shares of the company’s stock valued at $1,507,000 after purchasing an additional 13,438 shares during the last quarter. Squadron Capital Management LLC acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $6,550,000. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter worth $1,859,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.